Developer & Authority

Sonanos™ is developed by a pharmaceutical excipient manufacturer with extensive experience, particularly in the manufacture and sale of microcrystalline cellulose (Ceolus™) for tablet applications, supplying both domestic and international pharmaceutical companies. For corporate information and contact details, please refer to our official website.

Research Stage & Scientific Evidence

Sonanos™ has been evaluated through extensive in vitro and in vivo formulation studies. The data shown on this page are based on internal formulation experiments conducted under controlled laboratory conditions. To interpret results appropriately, please consider differences in API properties, experimental design, and formulation conditions.

Certifications & Quality Assurance

Our quality management systems are operated in accordance with internationally recognized standards to ensure consistent product quality and reliability.

Quality Management System : ISO 9001 Certified

Pharmaceutical Quality Compliance : We intend to comply with the international GMP guideline for pharmaceutical excipients, IPEC-PQG. Additionally, to ensure safe use in injectable formulations, we plan to comply with the ICH-Q3 impurity guideline.

Documentation : Test Results (results of quality analysis), Safety Data Sheets (SDS), statement document based on USDA Guideline 1105, and technical documentation are available upon request.

Please note that all certifications and compliance statements are based on our current operational scope and applicable facilities.

Safety & Biocompatibility

We possess non-GLP safety data for Sonanos™. Please refer to the latest Posters/presentations issued for conferences , which are available for download from our website upon free registration. Unpublished data or detailed study reports may also be available upon request.

Disclaimers

All information on this website is provided in good faith and believed correct, but Asahi Kasei Corporation undertakes no obligation, liability, warranty, or other responsibility, express or implied, for its completeness or accuracy. It is the responsibility of the user to determine the suitability of the product for the intended use, and the information herein is provided only on this condition. Asahi Kasei Corporation is under no obligation whatsoever, whether express or implied, in relation to any loss or damage occurring in or arising out of the use of any product or information described herein. This website does not represent and is not to be construed as a recommendation for any application or use of products, processes, equipment, or formulations described herein which may be in conflict with any valid patent. In relation to any and all of the above, Asahi Kasei Corporation is under no obligation or liability of any nature for any loss or damage, and undertakes no warranty relating thereto.

Intended Use

Sonanos™ is primarily designed for parenteral drugs. For Sustained Release Grade “Sonanos™ PG”, subcutaneous administration is recommended. For Solubility Enhancement Grade “Sonanos™ DS”, intravenous or subcutaneous administration is recommended.

Company Information

Asahi Kasei Corporation (Headquarters: Tokyo, Japan) is the leading manufacturer and supplier of functional pharma excipients, such as microcrystalline cellulose, in Japan. In order to further address the rising demands in formulation research, we are now developing a cutting-edge pharma excipient primarily for injections: hyaluronic acid nanogel, Sonanos™. The Sonanos™ can act as a DDS carrier, facilitating sustained release or solubility enhancement of APIs. For inquiries or sample requests, please use the “Contact us” link on this page.